Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current antiretroviral therapy].

P Bossi1, V Martinez, C Strady

  • 1Service de maladies infectieuses et tropicales, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris, France.

La Revue De Medecine Interne
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Oral oncology·2026
Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The microbiome in head and neck squamous cell carcinoma: Biological drivers, therapeutic interactions, and emerging clinical applications.

Critical reviews in oncology/hematology·2026
Same author

A multiomic framework for predicting laryngo-esophageal dysfunction following induction chemotherapy in hypopharyngeal-laryngeal carcinoma.

ESMO open·2025
Same author

Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy.

ESMO open·2025
Same author

The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.

Infectious diseases now·2025
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Effective HIV/AIDS treatment requires potent combination antiretroviral therapy. Careful drug selection and monitoring are crucial to overcome challenges like drug resistance and optimize antiviral activity.

Area of Science:

  • * Medical Virology and Immunology
  • * Pharmacology and Therapeutics

Context:

  • * Significant advances in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) therapy have led to stabilized epidemics in developed nations.
  • * Current standard treatment involves potent combination antiretroviral regimens, typically including nucleoside reverse transcriptase inhibitors and protease inhibitors or non-nucleoside reverse transcriptase inhibitors.
  • * Existing therapies face limitations such as side effects, drug resistance, adherence issues, and interactions.

Purpose:

  • * To review the current landscape of HIV/AIDS therapy, highlighting established treatment protocols.
  • * To discuss the challenges and limitations associated with current antiretroviral regimens.
  • * To explore strategies for optimizing treatment efficacy and managing drug resistance.

Related Experiment Videos

Summary:

  • * Potent combination antiretroviral therapy is recommended for HIV patients with detectable viral loads or immunologic dysfunction.
  • * Drug resistance is a primary cause of treatment failure, necessitating genotype/phenotype analysis for predicting clinical response.
  • * Individualized dosing and careful monitoring of combination therapy can minimize pharmacological issues and maximize antiviral effects.

Impact:

  • * Improved patient outcomes through optimized antiretroviral therapy selection and management.
  • * Potential to mitigate the impact of drug resistance on treatment success.
  • * Informs future research directions, including novel drug development, vaccines, and advanced therapies like cytokine and gene therapy.